Edwards Lifesciences Corp. Files 2023 Annual Report

TL;DR

<b>Edwards Lifesciences Corp. has filed its 2023 10-K annual report detailing its financial performance and business operations.</b>

AI Summary

Edwards Lifesciences Corp (EW) filed a Annual Report (10-K) with the SEC on February 12, 2024. Edwards Lifesciences Corp. filed its 10-K report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located at One Edwards Way, Irvine, CA 92614. Edwards Lifesciences Corp. is incorporated in Delaware. The Standard Industrial Classification code for the company is 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies).

Why It Matters

For investors and stakeholders tracking Edwards Lifesciences Corp, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Edwards Lifesciences' financial health, operational strategies, and risk factors for the fiscal year 2023, crucial for investors assessing the company's performance and future prospects. The detailed financial statements and disclosures within the report are essential for understanding the company's market position, revenue streams, and any potential challenges it faced or anticipates in the orthopedic, prosthetic, and surgical appliances sector.

Risk Assessment

Risk Level: medium — Edwards Lifesciences Corp shows moderate risk based on this filing. The company operates in the medical device industry, which is subject to significant regulatory oversight and rapid technological advancements, posing potential risks to market share and profitability.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Edwards Lifesciences' performance and strategic positioning in the medical device market.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period of report)
• 2024-02-12 — Filing Date (Date the report was filed)
• 2023-01-01 — Report Start Date (Beginning of the reporting period)

Key Players & Entities

• Edwards Lifesciences Corp. (company) — Filer name
• Irvine, CA (location) — Business address city and state
• Delaware (location) — State of incorporation
• 3842 (other) — Standard Industrial Classification code

Forward-Looking Statements

• Edwards Lifesciences will continue to operate under the same SIC code [3842] for the foreseeable future. (Edwards Lifesciences Corp.) — high confidence, target: 2025-12-31

FAQ

Industry Context

Edwards Lifesciences operates in the medical technology sector, specifically focusing on cardiovascular devices. This industry is characterized by innovation, regulatory scrutiny, and significant competition.

Regulatory Implications

The medical device industry is heavily regulated by bodies like the FDA, requiring strict adherence to quality standards and approval processes for products. Changes in healthcare policy can also impact market access and reimbursement.

What Investors Should Do

1. Analyze the financial statements for revenue trends, profitability, and debt levels.
2. Review the business description and risk factors for insights into operational strategies and potential challenges.
3. Compare key financial metrics with previous years to identify performance changes.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-02-12: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing data extracted for the 2023 10-K. Comparative data from previous filings would be needed for a direct comparison.

Key Financial Figures

• $1.00 — ch registered: Common Stock, par value $1.00 per share EW New York Stock Exchange S

Filing Documents

• ew-20231231.htm (10-K) — 2742KB
• ex-10310xkq42023.htm (EX-10.3) — 112KB
• ex-21110xkq42023.htm (EX-21.1) — 9KB
• ex-2310xkq42023.htm (EX-23) — 2KB
• ex-31110xkq42023.htm (EX-31.1) — 10KB
• ex-31210xkq42023.htm (EX-31.2) — 11KB
• ex-3210xkq42023.htm (EX-32) — 6KB
• ex-97110xkq42023.htm (EX-97.1) — 25KB
• ew-20231231_g1.jpg (GRAPHIC) — 99KB
• ew-20231231_g10.jpg (GRAPHIC) — 59KB
• ew-20231231_g11.jpg (GRAPHIC) — 24KB
• ew-20231231_g12.jpg (GRAPHIC) — 18KB
• ew-20231231_g13.jpg (GRAPHIC) — 25KB
• ew-20231231_g2.jpg (GRAPHIC) — 51KB
• ew-20231231_g3.jpg (GRAPHIC) — 34KB
• ew-20231231_g4.jpg (GRAPHIC) — 56KB
• ew-20231231_g5.jpg (GRAPHIC) — 48KB
• ew-20231231_g6.jpg (GRAPHIC) — 50KB
• ew-20231231_g7.jpg (GRAPHIC) — 49KB
• ew-20231231_g8.jpg (GRAPHIC) — 63KB
• ew-20231231_g9.jpg (GRAPHIC) — 65KB
• 0001099800-24-000004.txt (&nbsp;) — 19116KB
• ew-20231231.xsd (EX-101.SCH) — 97KB
• ew-20231231_cal.xml (EX-101.CAL) — 191KB
• ew-20231231_def.xml (EX-101.DEF) — 617KB
• ew-20231231_lab.xml (EX-101.LAB) — 1481KB
• ew-20231231_pre.xml (EX-101.PRE) — 1004KB
• ew-20231231_htm.xml (XML) — 3292KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 12 Item 1B. Unresolved Staff Comments 21 Item 1C. Cybersecurity 21 Item 2.

Properties

Properties 22 Item 3.

Legal Proceedings

Legal Proceedings 23 Item 4. Mine Safety Disclosures 24 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 25 Item 6. [Reserved] 26 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 43 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 93 Item 9A.

Controls and Procedures

Controls and Procedures 94 Item 9B. Other Information 94 Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 94 PART III Item 10. Directors, Executive Officers and Corporate Governance 95 Item 11.

Executive Compensation

Executive Compensation 95 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 95 Item 13. Certain Relationships and Related Transactions, and Director Independence 95 Item 14. Principal Accounting Fees and Services 95 PART IV Item 15. Exhibits and Financial Statement Schedules 96 Item 16. Form 10-K Summary 97

Signatures

Signatures 98 Table of Contents PART I NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend the forward-looking statements contained in this report to be covered by the safe harbor provisions of such Acts. Statements other than statements of historical or current fact in this report or referred to or incorporated by reference into this report are "forward-looking statements" for purposes of these safe harbor provisions. These statements can sometimes be identified by the use of the forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "pro forma," "forecast," "intend," "guidance," "optimistic," "aspire," "confident," other forms of these words or similar words or expressions or the negatives thereof. Statements regarding past performance, efforts, or results about which inferences or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results; these statements can be identified by the use of words such as "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions or the negatives thereof. These forward-looking statements are subject to substantial risks and uncertainties that could cause our results or future business, financial condition, results of operations or performance to differ materially from our historical results or experiences or those expressed or implied in any forward-looking statements contained in this report. These risks and uncertainties include, but are not limited to: the spin-off of our critical care product group, our ability to develop new products and avoid manufacturing and quality iss

Business

Item 1. Business Overview Edwards Lifesciences Corporation is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, we partner with the world's leading clinicians and researchers and invest in research and development to transform care for those impacted by structural heart disease or who require hemodynamic monitoring during surgery or in intensive care. Edwards Lifesciences has been a leader in our field for over six decades. Since our founder, Lowell Edwards, first dreamed of using engineering to address diseases of the human heart, we have steadily built a company on the premise of imagining, building, and realizing a better future for patients. A pioneer in the development of heart valve therapies, we are the world's leading manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Our innovative work in heart valves encompasses both surgical and transcatheter therapies for heart valve replacement and repair. In addition, our robust pipeline of future technologies is focused on the less invasive repair or replacement of the mitral and tricuspid valves of the heart, which are more complex and more challenging to treat than the aortic valve. We are also a global leader in hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. Cardiovascular disease is the number-one cause of death in the world and is the top disease in terms of health care spending in nearly every country. In the U.S. alone, one cardiovascular patient dies every 33 seconds. Cardiovascular disease is progressive in that it tends to worsen over time and often affects the structure of an individual's heart. Our vision is to transform patient care where patients are diagnosed earlier, treated in a routine fashion, living longer

View Full Filing

View this 10-K filing on SEC EDGAR